Revaccination With mRNA-1345 for RSV Maintains Robust Immunogenicity, Safety
Revaccination with mRNA-1345 against RSV at 12 months was noninferior to primary vaccination among adults aged 50 years and older.
Revaccination with Moderna’s mRNA-1345 vaccine for respiratory syncytial virus (RSV) is well tolerated and demonstrates noninferior immunogenicity compared with the primary dose, according to study results published in Clinical Infectious Diseases.
Investigators conducted a phase 3, randomized, multicenter clinical trial to assess the safety, tolerability, and antibody response of a 50-µg dose of mRNA-1345 vaccine administered 12 months after a primary dose in adults aged 50 years and older.
- They enrolled patients from 37 sites across the United States.
- Adults with underlying comorbidities that increased their risk for severe RSV infection were included.
According to study results published in Clinical Infectious Diseases.
Author's summary: mRNA-1345 revaccination shows promise.
More News
- 'Chainsaw Man - The Movie: Reze Arc' Review — A Beautifully Chaotic Anime
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- Town boss McKenna 'a candidate' for Celtic job... Our verdict on the rumour
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- PS5 vs PS4 Sales Comparison in the US - September 2025
- Gavin Newsom Says He Has 'No Interest' in Appearing on Joe Rogan's Podcast: 'I'm Moving On' | Video
- Pivoting from Exploration to Production: Mining's Moment
- US passport support in Apple Wallet is a hugely important step
- Travelzoo: Q3 Earnings Snapshot - WTOP News